AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36336245
Drug: Ivermectin Mass
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin Mass Drug Administration (MDA)
Trial: 34114623
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg dosing
Trial: 34641897
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist pretreatment for 3 days before stimulation
Trial: 34641897
Drug: Conventional GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional GnRH antagonist protocol (without pretreatment)
Trial: 34641897
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist pretreatment
Trial: 34448875
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg phosphorus (NaH2PO4)
Trial: 34152936
Drug: Indoor daylight
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoor daylight photodynamic therapy (idl-PDT)
Trial: 37838653
Drug: internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive behavioral therapy (iCBT)
Trial: 35304401
Drug: Demanding amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Demanding amoxicillin
Trial: 35304401
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not demanding any medicine)
Trial: 33819217
Drug: Exer-gaming for
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exer-gaming for 30 minutes twice a week for 8 weeks
Trial: 33819217
Drug: Balance training
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance training exercises twice a week for 8 weeks
Trial: 36425335
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with transfer factor capsules
Trial: 36425335
Drug: Cryotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy with transfer factor capsules
Trial: 34400956
Drug: Oral betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral betamethasone therapy (3 mg, once a week) with placebo
Trial: 34400956
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (15 mg, once a week) with placebo
Trial: 34400956
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate 15 mg, once a week and betamethasone 3 mg, once a week)
Trial: 36226802
Drug: Intralesional normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional normal saline solution (Control)
Trial: 33724296
Drug: Chemoradiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy with concurrent capecitabine (arm B)
Trial: 33603097
Drug: Organic carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Organic carbon exposure (increase of 0.51 μg/m3)
Trial: 33603097
Drug: Sodium exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium exposure (increase of 0.06 μg/m3)
Trial: 34304913
Drug: FDC IBU/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC IBU/APAP 250 mg/500 mg
Trial: 34304913
Drug: APAP 500
RxNorm normalized name: Mapap 500mg Caplet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP 500 mg
Trial: 34304913
Drug: FDC IBU/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC IBU/APAP 250 mg/500 mg, IBU 250 mg, APAP 500 mg
Trial: 34304913
Drug: FDC IBU/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC IBU/APAP 250 mg/500 mg, placebo
Trial: 32423576
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (1 g + 0.9% normal saline 100 mL)
Trial: 32423576
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (2 g + 0.9% normal saline 50 mL)
Trial: 34262263
Drug: AMPH ER
RxNorm normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMPH ER TAB (amphetamine extended-release tablet)
Trial: 32957900
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise program (REP, 50‐60% of 1RM, for 40‐50 min) combined with metformin
Trial: 32957900
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise program (AEP, 50‐70% maxHR, for 40‐50 min) combined with metformin
Trial: 32957900
Drug: Metformin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin without exercise intervention (Met group)
Trial: 35420554
Drug: Combination prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination prevention (CP) including intensive testing, linkage campaigns, expanded ART, and voluntary male medical circumcision referrals
Trial: 34620454
Drug: Fast Track
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast Track and Standard Treatment Trial (FASTT)
Trial: 34620454
Drug: Trying to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trying to conceive without treatment
Trial: 33684737
Drug: n−3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n−3 PUFA (2.2 g/day)
Trial: 33571959
Drug: Concurrent endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent endurance and strength training (n = 14)
Trial: 35029748
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy with phycocyanin
Trial: 35029748
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy with toluidine blue O
Trial: 35871490
Drug: Intralesional bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional bleomycin (1.5 mg/ml)
Trial: 35871490
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone (20 mg/ml)
Trial: 33840229
Drug: Benralizumab single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab single dose (30 mg)
Trial: 33840229
Drug: Benralizumab q4w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab q4w (30 mg every 4 weeks for a total of three doses)
Trial: 33840229
Drug: Benralizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (both dosing regimens)
Trial: 32275368
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with conventional symptomatic and supportive treatments
Trial: 32275368
Drug: Symptomatic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic and supportive treatments (control group)
Trial: 35114800
Drug: Neoadjuvant intraperitoneal‐systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant intraperitoneal‐systemic chemotherapy
Trial: 35114800
Drug: Paclitaxel +
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel + S‐1 (PS) chemotherapy
Trial: 33026517
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICG injection at 8 hours prior to surgery
Trial: 33026517
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICG injection at 10 hours prior to surgery
Trial: 33026517
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICG injection at 12 hours prior to surgery
Trial: 33026517
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICG injection at 14 hours prior to surgery
Trial: 36364825
Drug: Live Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Lactobacillus paracasei (L-PS23, 2 × 10^10 CFU/day)
Trial: 35235198
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG): 40–45 kcal and 1.5 g protein/kg/day; diet plus polymeric formula
Trial: 34202877
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride (3000 mg GlucosaGreen®)
Trial: 36424008
Drug: Tofogliflozin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofogliflozin (20 mg/d)
Trial: 36424008
Drug: Anagliptin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagliptin (200 mg/d)
Trial: 36067615
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks) for up to 24 months and 15 months respectively
Trial: 36067615
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus bevacizumab (15 mg/kg every 3 weeks) for up to 15 months
Trial: 36067615
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks)
Trial: 36067615
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus bevacizumab (15 mg/kg every 3 weeks)
Trial: 33789008
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg every 2 weeks for 16 weeks, followed by 480 mg every 4 weeks)
Trial: 34969541
Drug: Cholvax (Incepta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholvax (Incepta Vaccine Ltd)
Trial: 33026142
Drug: Short acting
RxNorm normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short acting BP medication added in the evening
Trial: 33026142
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication change (control)
Trial: 35255880
Drug: Barberry (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barberry (10 g/day dried barberry)
Trial: 32339447
Drug: hIL-7-hyFc (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hIL-7-hyFc (20, 60 μg/kg s.c. or 60 μg/kg i.m.)
Trial: 35867702
Drug: PegIFN alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN alfa‐2a (180 μg/week) for 48 weeks
Trial: 33561041
Drug: Forest Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forest Therapy (FT) intervention
Trial: 35849276
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate at a dose of 250 mg/kg (at 8 mg/kg/min) once daily for 3 days along with therapeutic hypothermia
Trial: 35849276
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate and therapeutic hypothermia
Trial: 34670201
Drug: Continuous theta
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous theta burst stimulation (cTBS) administered over one of three stimulation targets in randomized order.
Trial: 35979351
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments (historical controls)
Trial: 33326179
Drug: Aflibercept (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (2.0 mg/50 µl)
Trial: 33326179
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg/50 µl)
Trial: 32663660
Drug: Prolonged anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged anticoagulation (intravenous unfractionated heparin, subcutaneous enoxaparin, or intravenous bivalirudin) for at least 48 hours after pPCI
Trial: 35551533
Drug: Vaginal hormone-free
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal hormone-free moisturising cream
Trial: 35551533
Drug: Vaginal estriol
RxNorm normalized name: estriol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estriol (0.1%) cream
Trial: 32897015
Drug: Nefradoz (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefradoz (150 mg, 2 times a day for 28-30 days)
Trial: 32897015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (general recommendations and standard diet therapy for 28-30 days)
Trial: 34371810
Drug: Curcumin (HydroCurcTM;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (HydroCurcTM; 500 mg) with low dose iron (18 mg)
Trial: 34371810
Drug: Curcumin (HydroCurcTM;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (HydroCurcTM; 500 mg) with high dose iron (65 mg)
Trial: 34371810
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose iron (18 mg) with curcumin placebo
Trial: 34371810
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose iron (65 mg) with curcumin placebo
Trial: 35397622
Drug: 90 g/day low-carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g/day low-carbohydrate diet (LCD)
Trial: 33832346
Drug: Fluoropyrimidine (FP)
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluoropyrimidine (FP) therapy
Trial: 35816053
Drug: BNT162b2 as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 as second dose
Trial: 35816053
Drug: ChAdOx1 nCoV‐19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV‐19 as second dose
Trial: 35816053
Drug: CoronaVac as
RxNorm normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac as second dose
Trial: 35816053
Drug: Heterologous two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous two-dose schedules
Trial: 33628086
Drug: Pyridostigmine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 0.15 mg/kg + glycopyrrolate 0.4 mg (control group)
Trial: 32197627
Drug: Tailored cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored cognitive behavioural therapy
Trial: 33264516
Drug: Bimagrumab 30
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 30 mg/kg
Trial: 33264516
Drug: Bimagrumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab (both doses)
Trial: 32800842
Drug: Home BP
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home BP treatment
Trial: 32800842
Drug: Predialysis BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predialysis BP treatment
Trial: 34076379
Drug: Passiflora incarnata
RxNorm normalized name: Passiflora incarnata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passiflora incarnata L
Trial: 35726085
Drug: Digital therapeutics
RxNorm normalized name: digital therapeutics, amblyopia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital therapeutics (DTx) + guideline-based lifestyle modification consultation treatment as usual (TAU)
Trial: 35545190
Drug: Computer-guided sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-guided sodium hyaluronate injections
Trial: 35545190
Drug: Conventional sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sodium hyaluronate injections
Trial: 33576545
Drug: Oxycodone 10
RxNorm normalized name: oxycodone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 10 mg/Acetaminophen 650 mg
Trial: 33196737
Drug: USCCM cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USCCM cream and serum pre‐ and post‐ ablative resurfacing
Trial: 33196737
Drug: Vehicle pre‐procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle pre‐procedure cream
Trial: 34665204
Drug: Varenicline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline plus nicotine patch for 12 weeks
Trial: 34665204
Drug: Varenicline monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline monotherapy for 12 weeks
Trial: 34665204
Drug: Varenicline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline plus nicotine patch for 24 weeks
Trial: 34665204
Drug: Varenicline monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline monotherapy for 24 weeks
Trial: 32304283
Drug: Metformin/sitagliptin dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/sitagliptin dual therapy for 16 weeks
Trial: 32304283
Drug: Metformin/sitagliptin triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/sitagliptin triple therapy for 24 weeks
Trial: 32720187
Drug: Technosphere® Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere® Insulin (TI)
Trial: 32720187
Drug: Technosphere inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere inhalation powder without insulin (TP; placebo)
Trial: 32720187
Drug: Active-comparator treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-comparator treatment
Trial: 32720187
Drug: Active TI
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TI therapy
Trial: 36622539
Drug: Tecarfarin 30
RxNorm normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecarfarin 30 mg
Trial: 34218304
Drug: Montelukast (MON)
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast (MON) 10 mg once daily
Trial: 35653732
Drug: Dual-hormone algorithm-assisted
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dual-hormone algorithm-assisted insulin delivery (DH-AID)
Trial: 35653732
Drug: Single-hormone algorithm-assisted
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-hormone algorithm-assisted insulin delivery (SH-AID)
Trial: 33524314
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (300 mg orally once daily for 3 years)
Trial: 33524314
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral once daily for 3 years)
Trial: 33316362
Drug: Adaptive planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adaptive planning (AP) using a minimization algorithm, 36 Gy in 6 weekly fractions.
Trial: 33316362
Drug: Standard planning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard planning (SP), 36 Gy in 6 weekly fractions.
Trial: 35578194
Drug: Stabilizing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilizing group treatment (20 sessions, add-on to individual therapy)
Trial: 35578194
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy alone
Trial: 35578194
Drug: Stabilizing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilizing group treatment
Trial: 33710658
Drug: Conventional saphenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional saphenous vein graft preparation with low-pressure distension
Trial: 33496068
Drug: Candida antigen
RxNorm normalized name: Candida antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candida antigen (0.1 mL of Candida albicans antigen injected monthly in one patch of alopecia)
Trial: 33496068
Drug: Intralesional corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroid (0.1 mL of triamcinolone acetonide injected monthly in all alopecia patches)
Trial: 33023521
Drug: Guided counseling
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided counseling (monthly for four consecutive months)
Trial: 32315537
Drug: Antidepressant Treatment
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Treatment Record (ATR) classification level 1